Viridian Therapeutics, Inc. (VRDN) Tops Q3 EPS by 12c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q3 EPS of ($0.86), $0.12 better than the analyst estimate of ($0.98). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $303.33 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge